Evidence map›Paper›PMID 36340591›Full record

ReviewMaterials today. Bio2022

Mesoporous silicas in materials engineering: Nanodevices for bionanotechnologies.

Elisabetta Mazzotta, Marzia De Santo, Domenico Lombardo, Antonella Leggio, Luigi Pasqua

Abstract readReview
In one paragraph

Review in Materials today. Bio, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Elisabetta MazzottaExperimental Neurology Unit, School of Medicine and Surgery and Milan Center for Neuroscience, University of Milano-Bicocca, Via Cadore 48, 20900 Monza, Italy.
Marzia De SantoDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, Via P. Bucci, 87036 Arcavacata di Rende (CS), Italy.
Domenico LombardoInstitute for Chemical-Physical Processes, National Research Council, 98158 Messina, Italy.
Antonella LeggioDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, Via P. Bucci, 87036 Arcavacata di Rende (CS), Italy.
Luigi PasquaDepartment of Environmental Engineering University of Calabria, Via P. Bucci, 87036, Arcavacata di Rende (CS), Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this review, the most valuable opportunities offered by mesoporous silica nanoparticles in the field of development of nanodevices for bionanotechnology applications are reviewed. The state of the art is critically discussed with particular emphasis on cancer-related application, paying attention to all the aspects of the design and development of the process that engineers the selective administration of an anticancer agent to cancer tissues. The analyses of the critical factors that limit this process are taken into account and the technical solutions proposed to face these factors are discussed. Furthermore, targeting to difficult tissues and forefront applications such as cancer immunotherapy, diagnostic, theranostic, and gene therapy are considered. Lastly, the authors provide their opinion on the reasons according to which the translation of this generation of nanodevices from laboratory research into practical clinical and eventually into the market is possible.

Indexed as

Active targetingBionanotechnologyMesoporous silica nanoparticlesSmart chemotherapyStimuli responsivenessTargeted drug delivery

Identifiers

PMID36340591
PMCPMC9627595

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.